Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9385 - 9392 of 12089 results
The IRS's Proposed ABLE Regulations: Obstacles to Launching State Programs, and Potential Solutions
June 29, 2015| Blog| Viewpoint
FDA Reports Results of Annual Crack Down on Illegal Internet Pharmacies
June 26, 2015| Blog| Viewpoint
House Focuses on Environmental Regulations as Recess Looms
June 25, 2015| Blog| Viewpoint
SEC charges "Which EB-5" owners with securities law violations
June 25, 2015| Blog| Viewpoint
Toy Safety Regulation Should Be Left To The Federal Government
June 25, 2015| Blog| Viewpoint
Crowdfunding and IP in Health and Biotech Start-ups (Part 2): The JOBS Act
June 25, 2015| Blog| Viewpoint
Massachusetts Health Care Regulatory Review – Opportunity for Industry Comment
June 25, 2015| Blog| Viewpoint
Recognizable Faces Disappear from Facial Recognition Meetings
June 25, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|